TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment options under clinical evaluation for immature teratomas
Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: November 5, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Source links and citations
The following is an example of a national and/or institutional clinical trial that is currently being conducted:
AGCT1531 (NCT03067181) (Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients with GCTs): Patients with ovarian pure-cell immature teratomas that are Children's Oncology Group stage I (International Federation of Gynecology and Obstetrics [FIGO] stage IA and IB), grade 2 or 3, and have an AFP level of less than 1,000 ng/mL are eligible for surgery and observation on this trial.
Source links and citations
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Preserved source evidence · Not medical advice